Press Release
SAN DIEGO, CA, Jul 25, 2011 (MARKETWIRE via COMTEX) --
NuVasive, Inc. (NASDAQ: NUVA)
-- Total revenue of $133.0 million, up 11.2% over second quarter 2010 -- GAAP earnings of $5.4 million, or $0.13 per share -- Non-GAAP earnings of $12.4 million, or $0.30 per share -- Non-GAAP operating margin of 17.3% and GAAP operating margin of 8.6%
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today financial results for the quarter ended June 30, 2011.
NuVasive reported second quarter 2011 revenue of $133.0 million, an 11.2% increase over the $119.6 million for the second quarter 2010 and a 6.8% increase compared to $124.5 million for the first quarter 2011.
Gross profit for the second quarter 2011 was $107.5 million and gross margin was 80.8%, compared to a gross profit of $98.6 million and a gross margin of 82.4% for the second quarter 2010. For the first quarter 2011, gross profit was $100.9 million and gross margin was 81.1%.
Total operating expenses for the second quarter 2011 were $96.0 million compared to $90.3 million in the second quarter 2010 and $96.3 million in the first quarter 2011. The higher operating expenses in the second quarter 2011 compared to the prior year resulted primarily from additional costs associated with higher revenue and infrastructure expansion.
On a GAAP basis, the Company reported net income of $5.4 million, or $0.13 per share, for the second quarter 2011.
On a Non-GAAP basis, the Company reported net income of $12.4 million, or $0.30 per share, for the second quarter 2011. The Non-GAAP earnings per share calculations for the second quarter exclude (i) non-cash stock-based compensation of $7.7 million; (ii) certain intellectual property litigation expenses of $1.1 million; (iii) amortization of intangible assets of $1.4 million; (iv) acquisition related items of $1.3 million; and (v) non-cash interest expense on convertible notes of $0.1 million.
Cash, cash equivalents and short and long-term marketable securities were $524.2 million at June 30, 2011.
Alex Lukianov, Chairman and Chief Executive Officer, said, "Our financial performance in the second quarter of 2011 was excellent and suggests that we are executing well against our strategy to take market share. We generated industry leading revenue growth of over 11% and made progress against our profitability goals in spite of challenging spine market growth dynamics. We are exceptionally pleased with the outcome of our recent convertible notes offering, which bolsters our balance sheet and significantly enhances our financial flexibility. As our focus shifts toward the achievement of our next milestone, the evolution of NuVasive into a $1 billion revenue company, we are laser focused on maintaining the startup mentality that is the source of NuVasive's success as a prolific new product innovator. With Speed of Innovation(TM) as our competitive edge, we expect to continue to sustain industry leading growth."
2011 Full Year Financial Guidance
-- Revenue of $530 million to $540 million; unchanged from previous
guidance
-- GAAP EPS of $0.33 to $0.36; down from previous guidance of $0.52 to
$0.55 to reflect impact of new convertible notes placement
-- Non-GAAP EPS of $1.09 to $1.12; down from previous guidance of $1.20
to $1.23 to reflect impact of new convertible notes placement
-- Non-GAAP Operating Margin of ~17.5%, unchanged from previous guidance
-- GAAP effective tax rate of ~50%, up from previous guidance of ~45% to
reflect impact of new convertible notes placement
Reconciliation of Full Year EPS Guidance
------- --------------- ---------------
2010 2011 2011
Pre-Tax Pre-Tax Net of Tax*
------- --------------- ---------------
Low High Low High
Actual Range Range Range Range
------- ------- ------- ------- -------
GAAP earnings per share $ 0.64 $ 0.64 $ 0.69 $ 0.33 $ 0.36
Non-cash stock-based compensation 0.70 0.79 0.79 0.47 0.47
Certain intellectual property
litigation expenses 0.13 0.13 0.13 0.08 0.08
Amortization of intangible assets 0.13 0.18 0.18 0.11 0.11
Acquisition related items 0.07 0.04 0.04 0.02 0.02
Non-cash interest expense on
convertible notes - 0.15 0.15 0.09 0.09
------- ------- ------- ------- -------
Non-GAAP earnings per share $ 1.68 $ 1.92 $ 1.97 $ 1.09 $ 1.12
======= ======= ======= ======= =======
Weighted shares outstanding -
Diluted** 40,373 42,000 42,000 42,000 42,000
======= ======= ======= ======= =======
* Effective Tax Rate of ~50% applied to GAAP earnings and ~40% applied to
Non-GAAP adjustments
** Weighted average shares outstanding shown as pre "if-converted" method
Note: The new convertible notes will require mark-to-market accounting for
the bond hedge and conversion feature derivatives. The income (expense)
resulting from this accounting are expected to materially offset one another
and any impact would be excluded from non-GAAP earnings per share
calculations
2011 Full Year EPS Guidance Bridge for New Convertible Notes Impact
---------------------
Net of Tax*
---------------------
High
Low Range Range
--------- ---------
Prior GAAP earnings per share guidance $ 0.52 $ 0.55
Coupon interest expense of 2.75% on $402.5M (0.07) (0.07)
Amortization of issuance fees over 6 year life (0.01) (0.01)
Non-cash interest expense on convertible notes (0.08) (0.08)
Effective tax rate change (0.03) (0.03)
--------- ---------
Revised GAAP earnings per share guidance $ 0.33 $ 0.36
--------- ---------
Prior non-GAAP earnings per share guidance $ 1.20 $ 1.23
Coupon interest expense of 2.75% on $402.5M (0.07) (0.07)
Amortization of issuance fees over 6 year life (0.01) (0.01)
Effective tax rate change (0.03) (0.03)
--------- ---------
Revised non-GAAP earnings per share guidance $ 1.09 $ 1.12
--------- ---------
* New Effective Tax Rate of ~50% up from ~45%
2011 Guidance Reconciliation of Non-GAAP Operating Margin %
------------------------
FY 11
Estimate
------------------------
FY 10
Actual Prior Revised
------ ----------- -----------
Gross Margin % [A] 82.2% ~ 81% ~ 81%
Non-GAAP Research and Development [B] 8.0% ~ 8% ~ 7%
Non-cash stock-based compensation 0.7% ~ 1% ~ 1%
Acquisition related items* 0.4% as incurred as incurred
------ ----------- -----------
GAAP research and development 9.1% ~ 9% ~ 8%
Non-GAAP Sales, Marketing and
Administrative [C] 58.8% ~ 55.5% ~ 56.5%
Non-cash stock-based compensation 5.2% ~ 5% ~ 5%
Certain intellectual property litigation
expenses 1.1% ~ 1% ~ 1%
Acquisition related items* 0.2% ~ 0.5% & as ~ 0.5% & as
incurred incurred
------ ----------- -----------
GAAP sales, marketing and administrative 65.3% ~ 62% ~ 63%
Amortization of intangible assets 1.1% ~ 1.5% ~ 1.5%
------ ----------- -----------
Non-GAAP Operating Margin % [A-B-C] 15.4% ~ 17.5% ~ 17.5%
------ ----------- -----------
* Acquisition related items include ~0.5% of revenue for expenses associated
with prior M&A activity and as incurred
Reconciliation of Non-GAAP Information Management uses certain Non-GAAP financial measures such as Non-GAAP earnings per share, which exclude non-cash stock-based compensation, certain intellectual property litigation expenses, amortization of intangible assets, acquisition related items, and non-cash interest expense on convertible notes. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the Non-GAAP financial measures provided in this earnings release excluding these costs and uses these Non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these Non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These Non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from Non-GAAP measures used by other companies. Set forth below are reconciliations of the Non-GAAP financial measures to the comparable GAAP financial measure.
Reconciliation of Second Quarter 2011 Results
Pre-Tax Earnings
(in thousands, except per share data) Adjustments Net of Tax Per Share
------------ ----------- ----------
GAAP net income $ 5,380 $ 0.13
Non-cash stock-based compensation $ 7,725 4,635 0.11
Certain intellectual property
litigation expenses 1,099 659 0.02
Amortization of intangible assets 1,395 837 0.02
Acquisition related items 1,325 795 0.02
Non-cash interest expense on
convertible notes 96 58 0.00
----------- ----------
Non-GAAP earnings $ 12,364 $ 0.30
=========== ==========
Weighted shares outstanding - Diluted 40,868
==========
Reconciliation of Year To Date 2011 Results
Pre-Tax Earnings
(in thousands, except per share data) Adjustments Net of Tax Per Share
------------ ----------- ----------
GAAP net income $ 7,739 $ 0.19
Non-cash stock-based compensation $ 15,671 9,403 0.23
Certain intellectual property
litigation expenses 3,180 1,908 0.05
Amortization of intangible assets 2,737 1,642 0.04
Acquisition related items 1,896 1,138 0.03
Non-cash interest expense on
convertible notes 96 58 0.00
----------- ----------
Non-GAAP earnings $ 21,888 $ 0.54
=========== ==========
Weighted shares outstanding - Diluted 40,691
==========
Conference Call NuVasive will hold a conference call today at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com.
After the live webcast, the call will remain available on NuVasive's website, www.nuvasive.com, through August 24, 2011. In addition, a telephonic replay of the call will be available until August 8, 2011. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use pin number 375131.
About NuVasive NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedures for the spine. The Company is the 5th largest player in the $7.7 billion global spine market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With over 65 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
NuVasive, Inc.
Unaudited Condensed Consolidated Statement of Income
(in thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
------------------ ------------------
2011 2010 2011 2010
-------- -------- -------- --------
Revenue $132,966 $119,584 $257,432 $228,671
Cost of goods sold (excluding
amortization of purchased
technology) 25,508 21,014 49,034 40,457
-------- -------- -------- --------
Gross profit 107,458 98,570 208,398 188,214
Operating expenses:
Sales, marketing and
administrative 84,323 77,726 168,543 152,387
Research and development 10,258 11,205 21,027 21,904
Amortization of intangible assets 1,395 1,355 2,737 2,705
-------- -------- -------- --------
Total operating expenses 95,976 90,286 192,307 176,996
Interest and other expense, net:
Interest income 151 178 334 367
Interest expense (1,915) (1,668) (3,686) (3,337)
Other income (expense), net 80 (30) 577 87
-------- -------- -------- --------
Total interest and other expense,
net (1,684) (1,520) (2,775) (2,883)
-------- -------- -------- --------
Income before income tax expense 9,798 6,764 13,316 8,335
Income tax expense 4,776 574 6,316 1,439
-------- -------- -------- --------
Consolidated net income $ 5,022 $ 6,190 $ 7,000 $ 6,896
======== ======== ======== ========
Net loss attributable to
noncontrolling interests $ (358) $ (533) $ (739) $ (915)
======== ======== ======== ========
Net income attributable to NuVasive,
Inc. $ 5,380 $ 6,723 $ 7,739 $ 7,811
======== ======== ======== ========
Net income per share attributable to
NuVasive, Inc.:
Basic $ 0.14 $ 0.17 $ 0.19 $ 0.20
======== ======== ======== ========
Diluted $ 0.13 $ 0.17 $ 0.19 $ 0.19
======== ======== ======== ========
Weighted average shares outstanding:
Basic 39,786 39,242 39,701 39,071
======== ======== ======== ========
Diluted 40,868 40,694 40,691 40,383
======== ======== ======== ========
Stock-based compensation is included in operating expenses in the following
categories:
Sales, marketing and
administrative $ 7,124 $ 6,672 $ 14,459 $ 12,352
Research and development 601 877 1,212 1,631
-------- -------- -------- --------
$ 7,725 $ 7,549 $ 15,671 $ 13,983
======== ======== ======== ========
NuVasive, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
June 30, December 31,
2011 2010
------------- -------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 505,084 $ 92,597
Short-term marketable securities 14,545 86,458
Accounts receivable, net 80,532 76,632
Inventory 117,952 107,577
Deferred tax assets 4,425 4,425
Prepaid expenses and other current assets 4,724 4,082
------------- -------------
Total current assets 727,262 371,771
Property and equipment, net 115,566 102,165
Long-term marketable securities 4,603 50,635
Intangible assets, net 101,435 107,121
Goodwill 103,070 103,070
Deferred tax assets, non-current 52,033 52,033
Restricted cash and investments 68,613 5,529
Bond hedge derivative 80,098 -
Other assets 20,245 9,705
------------- -------------
Total assets $ 1,272,925 $ 802,029
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 52,447 $ 58,995
Accrued payroll and related expenses 15,356 17,266
Acquisition-related liabilities 33,955 32,715
------------- -------------
Total current liabilities 101,758 108,976
Senior Convertible Notes 543,696 230,000
Embedded conversion derivative 88,900 -
Long-term acquisition-related liabilities - 326
Deferred tax liabilities 3,685 3,685
Other long-term liabilities 12,670 12,810
Commitments and contingencies
Noncontrolling interests 11,138 11,877
Stockholders' equity:
Common stock 40 40
Additional paid-in capital 613,016 545,114
Accumulated other comprehensive income 1,698 616
Accumulated deficit (103,676) (111,415)
------------- -------------
Total stockholders' equity 511,078 434,355
------------- -------------
Total liabilities and stockholders' equity $ 1,272,925 $ 802,029
============= =============
NuVasive, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands)
Six Months Ended June 30,
----------------------------
2011 2010
------------- -------------
Operating activities:
Consolidated net income $ 7,000 $ 6,896
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 15,888 17,065
Stock-based compensation 15,671 13,983
Allowance for excess and obsolete
inventory 2,341 906
Allowance for doubtful accounts and sales
return reserve, net of write-offs 529 (1,007)
Accretion of contingent consideration 914 182
Other non-cash adjustments 2,893 2,591
Changes in operating assets and liabilities,
net of effects from acquisitions:
Accounts receivable (5,351) (8,514)
Inventory (12,146) (4,258)
Prepaid expenses and other current assets (791) (1,397)
Accounts payable and accrued liabilities (2,300) 4,128
Accrued payroll and related expenses (1,997) (5,574)
Income taxes payable 5,043 460
------------- -------------
Net cash provided by operating activities 27,694 25,461
Investing activities:
Purchases of property and equipment (27,944) (22,059)
Purchases of marketable securities (54,317) (95,015)
Sales of marketable securities 113,559 88,028
Purchases of restricted investments (4,701) -
Payment for specific rights in connection
with supply agreement, net of refund
received (5,000) -
------------- -------------
Net cash provided by (used in) investing
activities 21,597 (29,046)
Financing activities:
Proceeds from the sale of warrants 47,898 -
Proceeds from the issuance of convertible
debt, net of issuance costs 391,548 -
Purchase of convertible note hedges (80,097) -
Proceeds from the issuance of common stock 4,334 11,963
Other assets (557) 1,369
Tax benefits related to stock-based
compensation awards - (7,481)
------------- -------------
Net cash provided by financing activities 363,126 5,851
Effect of exchange rate changes on cash 70 (166)
------------- -------------
Increase in cash and cash equivalents 412,487 2,100
Cash and cash equivalents at beginning of
period 92,597 65,413
------------- -------------
Cash and cash equivalents at end of period $ 505,084 $ 67,513
============= =============
Contact: Michael J. Lambert EVP & Chief Financial Officer NuVasive, Inc. 858-909-3394 Email Contact Investors: Patrick F. Williams Vice President, Industry & Investor Relations NuVasive, Inc. 858-638-5511 Email Contact Media: Nicholas S. Laudico The Ruth Group 646-536-7030 Email Contact
SOURCE: NuVasive, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=8BA19B788979FAE5 http://www2.marketwire.com/mw/emailprcntct?id=90DA38FE19EAC05D http://www2.marketwire.com/mw/emailprcntct?id=76CD34FAFD2E2C3C